First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the KINCISE 2tm Surgical Automated System, a next-generation automated power tool4,7 ...

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

In 1989, Johnson & Johnson sold its talc subsidiary. Instead of taking the opportunity to transition Johnson’s Baby Powder ...

Cadinha & Co. dramatically reduced its Johnson & Johnson holdings by 87.2% last quarter, slashing shares from 124,998 to ...

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting ...

Choosing dividend stocks is not only about looking at the yield but also ensuring that the company pays regular dividends, ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Pharmaceutical stocks may continue their slump in the near term. Last Thursday, President Trump sought to lower drug prices. The President is targeting foreign countries that pay less for medication.

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...

As one of the leading institutions for photochemical sciences research, Bowling Green State University continues to partner ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...